Unidentified Investor's questions to Scinai Immunotherapeutics Ltd (SCNI) leadership • Q2 2024
Question
An unidentified investor asked for management's perspective on the company's current valuation and the key factors that suggest it is undervalued.
Answer
CEO Amir Reichman stated his belief that Scinai is undervalued compared to preclinical peers. He highlighted the derisked pipeline from the Max Planck Institute, the unique CDMO business unit, and the recent EIB debt-to-equity deal that resolved a ~$29 million liability and significantly improved shareholder equity. Reichman also cited multi-billion dollar valuations of comparable companies like Apogee and MoonLake Immunotherapeutics, noting Scinai's broader pipeline of nine nanobodies offers massive potential.